A study comparing the effectiveness of pomegranate versus Gabapentin for treatment of Diabetic nephropathy in patients of diabetus melitus type

A study comparing the effectiveness of pomegranate versus Gabapentin for treatment of Diabetic nephropathy in patients of diabetus melitus type 2

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N137

Enrollment

Registered

2020-03-15

Start date

2013-08-01

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention 1: Intervention group: In the pomegranate medicine group, patients are given pomegranate tablet (225 milligram - Amin.Co Iran)half pills every 12 hours for 3 months. Intervention 2: Inter

Eligibility

Sex/Gender

All

Age

30 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes who have painful lower extremity nephropathy for at least 3 months Age between 70 and 30 years Do not take pomegranate pills. Do not have severe physical, neurological or psychiatric illness. Do not become pregnant or breast-feeding.

Exclusion criteria

Exclusion criteria: Severe sensitivity to pomegranate pills Severe grade 4 heart failure or unstable angina HbA1c greater than or equal to 8.5

Design outcomes

Primary

Measure	Time frame
Lower extremity nephropathy. Timepoint: Start and 3 months after intervention. Method of measurement: Examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Javad Tabaeyan

Arak University of Medical Sciences

Tabaeean@arakmu.ac.ir+98 634173638

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026